Lexaria Bioscience (LEXX) Short-term Investments (2018 - 2025)
Lexaria Bioscience (LEXX) posted Short-term Investments of $143267.0 for Q4 2025, up 548.47% sequentially from $22093.0 in Q3 2025, and up 259.29% YoY from $39875.0 in Q4 2024.
Lexaria Bioscience (LEXX) Short-term Investments (2018 - 2025) Analysis & Trends
Lexaria Bioscience has reported Short-term Investments for 8 years, with the latest figure at $143267.0 in Q4 2025.
- Quarterly Short-term Investments rose 259.29% year-over-year to $143267.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $143267.0 (up 259.29% YoY) and the FY2025 annual result came in at $22093.0, changed N/A from the prior year.
- Short-term Investments climbed to $143267.0 in Q4 2025 per LEXX's latest filing, from $22093.0 in the prior quarter.
- Over five years, Short-term Investments peaked at $833841.0 in Q3 2021 and troughed at $22093.0 in Q3 2025.
- A 5-year average of $254634.8 and a median of $267704.0 in 2023 frame the typical range for Short-term Investments.
- The sharpest annual moves came in 2021 and 2024: Short-term Investments surged 4215.72% in 2021, then plunged 82.82% in 2024.
- Over 5 years, Short-term Investments stood at $493424.0 in 2021, then tumbled by 45.34% to $269707.0 in 2022, then tumbled by 73.15% to $72427.0 in 2023, then plunged by 44.94% to $39875.0 in 2024, then jumped by 259.29% to $143267.0 in 2025.
- According to Business Quant data, Short-term Investments over the past three periods registered $143267.0, $22093.0, and $33540.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 143,267.00 |
| Aug 31, 2025 | 22,093.00 |
| May 31, 2025 | 33,540.00 |
| Feb 28, 2025 | 73,915.00 |
| Nov 30, 2024 | 39,875.00 |
| May 31, 2024 | 46,307.00 |
| Feb 29, 2024 | 87,699.00 |
| Nov 30, 2023 | 72,427.00 |
| Aug 31, 2023 | 125,642.00 |
| May 31, 2023 | 269,560.00 |
| Feb 28, 2023 | 267,704.00 |
| Nov 30, 2022 | 269,707.00 |
| Aug 31, 2022 | 347,335.00 |
| May 31, 2022 | 288,032.00 |
| Feb 28, 2022 | 552,317.00 |
| Nov 30, 2021 | 493,424.00 |
| Aug 31, 2021 | 833,841.00 |
| May 31, 2021 | 400,744.00 |
| Feb 28, 2021 | 470,632.00 |
| Nov 30, 2020 | 43,731.00 |